Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW
- DOI
- 10.1186/s12933-025-03002-1
- Published
- 2025-12-20
- Container
- Cardiovascular Diabetology
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s12933-025-03002-1,
title = {Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW},
author = {Peter Rossing and Morten Lindhardt and Christian Klyver Tikkanen and Jyothi Menon and Juliette Cattin and Barnaby Hunt and Samuel J. P. Malkin and Barrie Chubb and Tina Damgaard and Rikke Borg},
year = {2025},
journal = {Cardiovascular Diabetology},
doi = {10.1186/s12933-025-03002-1},
url = {https://doi.org/10.1186/s12933-025-03002-1}
}RIS
TY - JOUR TI - Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW AU - Peter Rossing AU - Morten Lindhardt AU - Christian Klyver Tikkanen AU - Jyothi Menon AU - Juliette Cattin AU - Barnaby Hunt AU - Samuel J. P. Malkin AU - Barrie Chubb AU - Tina Damgaard AU - Rikke Borg PY - 2025 JO - Cardiovascular Diabetology DO - 10.1186/s12933-025-03002-1 UR - https://doi.org/10.1186/s12933-025-03002-1 ER -
APA
Rossing, P., Lindhardt, M., Tikkanen, C. K., Menon, J., Cattin, J., Hunt, B., Malkin, S. J. P., Chubb, B., Damgaard, T., & Borg, R. (2025). Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-025-03002-1
Source records
- crossref · retrieved 2026-09-26T05:28:11.552Z